|
| Status |
Public on Mar 01, 2011 |
| Title |
Tasquinimod, a Quinoline-3-Carboxamide Anti-Angiogenic Agent, treated Prostate Cancer Cell Line in-vivo and in-vitro |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
The quinoline-3-carboxamide ABR-215050 (Tasquinimod (INN)), exhibits anti-tumor activity via inhibition of tumor angiogenesis in human and rodent tumors. To further explore the mode of action of ABR-215050, in vivo experiments with gene microarray analysis were performed using samples of LNCaP prostate tumors excised from nude mice exposed to ABR-215050 for 24h at 10 mg/kg(ad.lib.). The array data were validated by real-time PCR (sqRT-PCR), as well as by protein expression experiments. Among several significant differentially expressed gene after exposure to ABR-215050, were cytokine receptor CXCR4, cytochrome P450 1A1 (CYP1A1), thrombospondin-1 (THBS1) and Lysyloxidase preprotein (LOX).
To further explore the mode of action of ABR-215050, in vitro experiments with gene microarray analysis were performed using LNCaP prostate tumor cells. The array data were validated by real-time PCR (sqRT-PCR), as well as by protein expression experiments. One of the most significant differentially expressed genes after exposure to ABR-215050, was thrombospondin-1 (THBS1).
|
| |
|
| Overall design |
2-color treatment vs. control microarray experiment comprising four biological replicates. Each biological replicate was hybridized with dye-swap; resulting in eight hybridizations for each dataset (in vitro and in vivo), for a total of 16 hybridizations.
|
| |
|
| Contributor(s) |
Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T |
| Citation(s) |
20470445 |
| Submission date |
Jul 09, 2009 |
| Last update date |
Mar 21, 2012 |
| Contact name |
Johan Vallon-Christersson |
| Organization name |
Lund University
|
| Department |
Department of Oncology, Clinical Sciences
|
| Street address |
Lund University
|
| City |
Lund |
| ZIP/Postal code |
SE-221 85 |
| Country |
Sweden |
| |
|
| Platforms (2) |
|
| Samples (8)
|
| GSM426047 |
In vivo exp 1 LNCaP 10mg kg ABR-215050 24h |
| GSM426048 |
In vivo exp 2 LNCaP 10mg kg ABR-215050 24h |
| GSM426049 |
In vivo exp 3 LNCaP 10mg kg ABR-215050 24h |
| GSM426050 |
In vivo exp 4 LNCaP 10mg kg ABR-215050 24h |
| GSM426051 |
In vitro exp 1 LNCaP 50µM ABR-215050 24h |
| GSM426052 |
In vitro exp 2 LNCaP 50µM ABR-215050 24h |
| GSM426053 |
In vitro exp 3 LNCaP 50µM ABR-215050 24h |
| GSM426054 |
In vitro exp 4 LNCaP 50µM ABR-215050 24h |
|
| Relations |
| BioProject |
PRJNA117795 |
Less...
More...